Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation
Study sponsor: Kiniksa Pharmaceuticals International, plc · KNSA
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-11-12Actual
Enrollment · participants814Actual
Source updated2025-01-22Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.